Franklin Resources Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Franklin Resources Inc. raised its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 2.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,869,632 shares of the company's stock after acquiring an additional 87,262 shares during the period. Franklin Resources Inc. owned approximately 3.84% of Day One Biopharmaceuticals worth $55,336,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock valued at $51,000 after purchasing an additional 1,002 shares during the last quarter. Quest Partners LLC lifted its stake in Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after acquiring an additional 7,668 shares during the period. SG Americas Securities LLC purchased a new position in shares of Day One Biopharmaceuticals in the 2nd quarter worth approximately $113,000. Point72 DIFC Ltd purchased a new stake in shares of Day One Biopharmaceuticals during the second quarter valued at $124,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Day One Biopharmaceuticals during the second quarter worth $163,000. Institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Stock Up 0.2 %

Day One Biopharmaceuticals stock traded up $0.02 during trading hours on Tuesday, hitting $12.64. The stock had a trading volume of 924,103 shares, compared to its average volume of 957,777. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -12.27 and a beta of -1.51. The business's 50 day simple moving average is $14.15 and its 200-day simple moving average is $14.03. Day One Biopharmaceuticals, Inc. has a one year low of $11.94 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analysts' expectations of $15.05 million. During the same quarter in the previous year, the firm earned ($0.54) EPS. Research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on DAWN. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $35.71.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 10,000 shares of the company's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $16.10, for a total value of $161,000.00. Following the transaction, the insider now directly owns 1,057,535 shares of the company's stock, valued at approximately $17,026,313.50. This represents a 0.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 51,745 shares of company stock worth $748,567. 8.40% of the stock is currently owned by insiders.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.